Delving into the Latest Updates on LN-145-S1 with Synapse

Overview

Basic Info

Drug Type

TIL therapy

Synonyms

PD-1 Seleted TIL, LN 145-S1, LN-145-S1

Target-

Mechanism

T lymphocyte replacements

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [2]

Active Indication

MelanomaAnaplastic Thyroid CarcinomaChondrosarcoma+ [12]

Inactive Indication

Squamous cell carcinoma of head and neck metastatic

Originator Organization

Iovance Biotherapeutics, Inc.

Active Organization

Iovance Biotherapeutics, Inc.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. LN-145-S1 is made using a modified process that chooses a specific portion of the T-cells. The T cells may specifically recognize, target, and kill the tumor cells.

Start Date27 Apr 2018

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+2]

NCT03083873 / CompletedPhase 2

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145/LN-145-S1) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Start Date09 Jan 2017

Sponsor / Collaborator

Iovance Biotherapeutics, Inc.

100 Clinical Results associated with LN-145-S1

Login to view more data

100 Translational Medicine associated with LN-145-S1

Login to view more data

100 Patents (Medical) associated with LN-145-S1

Login to view more data

100 Deals associated with LN-145-S1

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma	Phase 2	US	Iovance Biotherapeutics, Inc.	21 Mar 2022
Anaplastic Thyroid Carcinoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Chondrosarcoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Giant Cell Tumor of Bone	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Malignant Fibrous Histiocytoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Malignant Solid Neoplasm	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Metastatic osteosarcoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Osteosarcoma, Recurrent	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Ovarian Carcinosarcoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018
Platinum-Resistant Ovarian Carcinoma	Phase 2	US	Iovance Biotherapeutics, Inc.	27 Apr 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03083873 (CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic	64	LN-145 (Cohort 1)	ouujxaficm(fvleaulsbn) = umbmbqymgz mjtctdvdth (vlcnktoccq, aqdlfblvvg - lpqtxrpibp) View more	-	12 Oct 2023
				LN-145 (Cohort 2)	ouujxaficm(fvleaulsbn) = fqadvjhtld mjtctdvdth (vlcnktoccq, vdyxrudpba - jpmtwmoima) View more